Evaluation of clinical outcomes with alvimopan in clinical practice: A national matched-cohort study in patients undergoing bowel resection

Annals of Surgery

Volumn 255, Issue 4, 2012, Pages 731-738

  Delaney, Conor P ^a   Craver, Christopher ^b   Gibbons, Melinda M ^c   Rachfal, Amy W ^d   Vandepol, Christine J ^e   Cook, Suzanne F ^f   Poston, Sara A ^f   Calloway, Michael ^f   Techner, Lee ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Premier Research   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^d ADOLOR CORPORATION   (United States)

^e EnPharma Consulting Inc   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVIMOPAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; INFECTION; INTENSIVE CARE UNIT; INTESTINE RESECTION; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANASTOMOSIS, SURGICAL; COHORT STUDIES; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GASTROINTESTINAL AGENTS; HOSPITAL COSTS; HUMANS; INTENSIVE CARE UNITS; INTESTINES; LAPAROSCOPY; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT READMISSION; PIPERIDINES; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84858697941     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824a36cc     Document Type: Article

References (46)

1. Iyer S, Saunders WB, Stemkowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Manag Care Pharm. 2009;15:485-494.
2. Schuster TG, Montie JE. Postoperative ileus after abdominal surgery. Urology. 2002;59:465-471. (Pubitemid 34249863)
3. Chang SS, Baumgartner RG, Wells N, et al. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol. 2002;167:208-211. (Pubitemid 34024533)
4. Augestad KM, Delaney CP. Postoperative ileus: impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathways. World J Gastroenterol. 2010;16:2067-2074.
5. Behm B, Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol. 2003;1:71-80. (Pubitemid 37248077)
6. Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut. 2009;58:1300-1311.
7. Delaney CP, Senagore AJ, Gerkin TM, et al. Association of surgical care practices with length of stay and use of clinical protocols after elective bowel resection: results of a national survey. Am J Surg. 2010;199:299-304. Discussion 304.
8. Gouvas N, Tan E, Windsor A, et al. Fast-track vs standard care in colorectal surgery: a meta-analysis update. Int J Colorectal Dis. 2009;24:1119-1131.
9. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000;87:1480-1493.
10. Kehlet H. Multimodal approach to postoperative recovery. Curr Opin Crit Care. 2009;15:355-358.
11. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001; 182(suppl):3S-10S. (Pubitemid 34072941)
12. Lassen K, Soop M, Nygren J, et al. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg. 2009;144:961-969.
13. Luckey A, Livingston E, Tache Y.Mechanisms and treatment of postoperative ileus. Arch Surg. 2003;138:206-214. (Pubitemid 36216289)
14. Wind J, Polle SW, Fung K, on Jin PH, et al. Systematic review of enhanced recovery programmes in colonic surgery. Br J Surg. 2006;93:800-809. (Pubitemid 44035251)
15. Mukherjee A, Senagore AJ, Delaney CP. Postoperative care pathways. Semin Colon Rectal Surg. 2005;16:215-227.
16. Adolor Corporation/Cubist Pharmaceuticals. Entereg prescribing information. 2009. Available at: http://www.entereg.com/
17. Adolor Corporation. Adolor and GlaxoSmithKline announce FDA approval of Entereg R(alvimopan) for the management of postoperative ileus (POI) [press release]. Exton and Philadelphia, PA: Adolor Corporation; May 20, 2008.
18. Delaney CP, Chang E, Senagore AJ, et al. Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database. Ann Surg. 2008;247:819-824. (Pubitemid 351591517)
19. Absher RK, Gerkin TM, Banares LW. Alvimopan use in laparoscopic and open bowel resections: clinical results in a large community hospital system. Ann Pharmacother. 2010;44:1701-1708.
20. Stukel TA, Fisher ES,Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278-285. (Pubitemid 46143305)
21. Hall BL, Bilimoria KY, Ko CY. Investigations using clinical data registries: observational studies and risk adjustment. Surgery. 2009;145:602-610.
22. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects-advantages and disadvantages. Nat Clin Pract Rheumatol. 2007;3:725-732. (Pubitemid 350187018)
23. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303:2359-2367.
24. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358:771-783. (Pubitemid 351284455)
25. Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:2035-2042.
26. Stulberg JJ, Delaney CP, Neuhauser DV, et al. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA. 2010;303:2479-2485.
27. Charlson ME, Pompei P,AlesKL, et al.Anewmethod of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronicDis. 1987;40:373-383. (Pubitemid 17055592)
28. Agency for Healthcare Research and Quality. HCUP Chronic condition indicator. Healthcare Cost and Utilization Project; 2009.
29. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(Pt 2):757-763. (Pubitemid 27446562)
30. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33-38.
31. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med. 1991;115:901-905.
32. D'Agostino RB, Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
33. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137:693-695. (Pubitemid 35176104)
34. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330-1342.
35. WolffBG, Michelassi F, Gerkin TM, et al. Alvimopan Postoperative Ileus Study Group. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240:728-734. Discussion 734-735
36. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006;20:64-70. (Pubitemid 43097035)
37. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098-1105.
38. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005;48:1114-1125. Discussion 1125-1126. Author reply 1127-1129.
39. Buchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312-325.
40. Wolff BG, Weese JL, Ludwig KA, et al. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg. 2007;204:609-616. (Pubitemid 46428581)
41. Rittner HL, Roewer N, Brack A. The clinical (ir)relevance of opioid-induced immune suppression. Curr Opin Anaesthesiol. 2010;23:588-592.
42. Person B, Wexner SD. The management of postoperative ileus. Curr Probl Surg. 2006;43:6-65.
43. Suljagic V, Jevtic M, Djordjevic B, et al. Surgical site infections in a tertiary health care center: prospective cohort study. Surg Today. 2010;40:763-771.
44. Bell TJ, Poston SA, Kraft MD, et al. Economic analysis of alvimopan in North American Phase III efficacy trials. Am J Health Syst Pharm. 2009;66:1362-1368.
45. Poston SB, Broder MS, Gibbons MD, et al. The impact of alvimopan on hospital cost after bowel resection: results from a large inpatient database. P T. 2011;36:209-212, 217-220.
46. Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Institute of Medicine of the National Academies; 2007.